Hepatitis C: Risk Stratification and Public Health Strategies
Nov
2026
Description
This session covers post-SVR risk stratification for HCC and liver-related outcomes in hepatitis C, plus novel diagnostics and public health strategies for testing and treatment in high-risk populations.
Presentations
5:00 PM
- 5:15 PM
Convention Center - Bluebird Ballroom 3ABC
SAFE-HCV Score for Hepatocellular Carcinoma Surveillance After Direct-Acting Antiviral Therapy in Hepatitis C Patients with Sustained Virologic Response
Jonggi Choi | Abstract Presenter
5:15 PM
- 5:30 PM
Convention Center - Bluebird Ballroom 3ABC
Post-SVR Liver Stiffness Measurement and Risk of Major Adverse Liver Outcomes and Hepatocellular Carcinoma in Veterans With Chronic Hepatitis C and Without Cirrhosis
Binu V. John | Abstract Presenter
5:30 PM
- 5:45 PM
Convention Center - Bluebird Ballroom 3ABC
NMR-based serum metabolomics identifies a 7‑metabolite panel that discriminates HCV-related cirrhosis from chronic hepatitis C
SUMIT RUNGTA, DM GASTRO | Abstract Presenter
5:45 PM
- 6:00 PM
Convention Center - Bluebird Ballroom 3ABC
A Novel point of care test for detection of HCV antigens using Smart Polymer technology: a prospective multinational study
Riham Soliman, PhD | Abstract Presenter
6:00 PM
- 6:15 PM
Convention Center - Bluebird Ballroom 3ABC
An opportunistic LIS-based Strategy to Recapture Patients with Active HCV: Efficacy and Cost-Effectiveness of Prolink-C in Spain
Federico Garcia | Abstract Presenter
6:15 PM
- 6:30 PM
Convention Center - Bluebird Ballroom 3ABC
Changes in prevalence of hepatitis C and self-reported hepatitis C testing, diagnosis, and treatment among persons who inject drugs — National HIV Behavioral Surveillance, 2018, 2022, and 2024
Megan G. Hofmeister, MD, MS, MPH | Abstract Presenter
